Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 4/20 | 0.48 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632541 | 0.92 | SLC6A4 (0.57) | SLC6A4ARSCN8ASCN10ASLC22A12 | |
| SCHEMBL16632675 | 0.91 | AR (0.53) | SLC6A4ARSCN8ASCN10ANR3C1 | |
| SCHEMBL16632458 | 0.90 | SLC6A4 (0.60) | SLC6A4ARESRRASLC6A2SLC6A3 | |
| SCHEMBL16632419 | 0.88 | AR (0.52) | SLC6A4ARSLC6A2SLC6A3KCNH2 | |
| SCHEMBL16632358 | 0.84 | NCEH1 (0.38) | SLC6A4ARSLC22A12NR3C1NR3C2 | |
| SCHEMBL16632568 | 0.84 | AR (0.54) | SLC6A4ARSCN8ASCN10ANR3C1 | |
| SCHEMBL16632414 | 0.84 | AR (0.53) | SLC6A4ARSCN8ASCN10ASLC22A12 | |
| SCHEMBL16640622 | 0.83 | AR (0.54) | SLC6A4ARSCN8ASCN10ASLC22A12 | |
| SCHEMBL4175734 | 0.81 | AR (0.59) | SLC6A4ARSCN8ASCN10ASLC22A12 | |
| SCHEMBL16632331 | 0.81 | SLC6A4 (0.58) | SLC6A4ARSLC22A12ESRRASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | SLC6A4 4266/4885AR 3070/4885SCN8A 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.